Hiroki Hayashi

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy

Xudong Liao, Yuyan Shen, Rongli Zhang et al. · Proceedings of the National Academy of Sciences · 2018 · 187 citations · Full text

Life Sciences, Cardiology, Physiology +17

Convergence of G Protein–Coupled Receptor and S-Nitrosylation Signaling Determines the Outcome to Cardiac Ischemic Injury

Z. Maggie Huang, Erhe Gao, Fábio V. Fonseca et al. · Science Signaling · 2013 · 106 citations

Life Sciences, Cardiology, Physiology +17

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 104 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Importance of Vital Signs to the Early Diagnosis and Severity of Sepsis: Association between Vital Signs and Sequential Organ Failure Assessment Score in Patients with Sepsis

Tsuneaki Kenzaka, Masanobu Okayama, Shigehiro Kuroki et al. · Internal Medicine · 2012 · 93 citations · Full text

Veterinary Medicine, Internal Medicine, Critical Care Medicine +16